Evaluating the Durability & Biomarkers of Tolerance & Exploring Delivery Systems to Drive Antigen-Specific Immune Tolerance Approaches to Achieve Clinical Efficacy
The 10th Antigen-Specific Immune Tolerance Summit returns at a defining moment for the field. With Diamyd Medical generating pivotal Phase III data, COUR Pharmaceuticals reporting clinical findings from treated patients, and companies including Bonsai Biotherapeutics and Parvus Therapeutics, advancing novel antigen-specific immune tolerance therapies.Therefore, ASIT is entering a critial phase of clinical validation. Yet, as more programs mature, the focus is shifting from demonstrating biological activity to proving durable clinical efficacy, defining meaningful biomarkers of tolerance, and generating the evidence needed to secure regulatory approval and attract investment.
This year's meeting is focused on driving immune tolerance strategies into clinical efficacy and the challenges the community needs to overcome to do just that. We’re celebrating a decade of bringing together the autoimmune and immunology senior decisionmakers, biotech innovators, key-opinion leaders and investors advancing antigen-specific approaches,
Join the community leading the most important conversations in the field of immune tolerance, as the only industry led meeting dedicated exclusively to antigen-specific stratergies. Providing you with the chance to engage directly with the decision-makers and experts driving progress across autoimmune and allergy. Don't miss the 10th anniversary summit where the future of immune tolerance will be debated, challenged, and defined, as part of the World Immune Tolerance Week bringing together the 10th Antigen-Specific Immune Tolerance Summit, 9th Treg-Directed Therapies Summit, and 2nd Immune Resetting: B-Cell Mediated & Beyond Summit under one roof.
-
It is truly the annual meeting in the ASIT field, bringing together a community dedicated to sharing knowledge, exchanging insights, and celebrating the advances shaping the field.
Chief Executive Officer, Bonsai Biotherapeutics
-
As antigen-specific tolerance rapidly transitions from concept to clinic, this summit stands out as a unique forum bridging immunology, bioengineering, and therapeutic development.
Instructor, Division of Immunology & Rheumatology, Stanford University
Co-Founder & Scientific Advisor, EBVio
-
The whole program was very informative. The collegial spirit and sharing of information was very refreshing, with everyone interested in seeing the field succeed and recognizing that success for one was a success for all.
Vice President Corporate Strategy, GSK
-
The Antigen-Specific Immune Tolerance Summit continues to succeed, thanks to engaging conference topics and active interest from participants. This year's event was another enjoyable and rewarding experience.
Professor, University of Basel
Explore the Full Event Guide
- Gain a first look at the 2027 ASIT priorities shaping the future of immune tolerance and identify where your research, platform, or partnership strategy fits within the evolving landscape
- Discover dedicated workshop sessions focused on biomarkers of tolerance, pre-clinical models and translational development
- Look forward to a panel dedicated to investment readiness to help de-risk and accelerate therapeutic development.
- Maximise your onsite experience and Connect with 180+ autoimmune and immunology leaders, as part of World Immune Tolerance Week to build partnerships and advance your program.
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest ASIT industry breakthroughs and gain exclusive insights into the packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside leading drug developers and solution providers in this tight-knit community to ensure your brand is at the heart of the ASIT field.
Join Biopharma Experts
Be part of the hottest conversations with a specially curated audience of 60+ experts from like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.